Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
7
BJDX Quote, Financials, Valuation and Earnings
Last price:
$0.76
Seasonality move
:
-28.24%
Day range:
$0.78 - $0.89
52-week range:
$0.78 - $10.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.39x
Volume:
157.6K
Avg. volume:
105.1K
1-year change:
-79.49%
Market cap:
$1.5M
Revenue:
--
EPS (TTM):
-$32.24
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bluejay Diagnostics, Inc. has 1599900% upside to fair value with a price target of -- per share.
BJDX vs. S&P 500
-
Over the past 5 trading days, Bluejay Diagnostics, Inc. has underperformed the S&P 500 by -23.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bluejay Diagnostics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bluejay Diagnostics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bluejay Diagnostics, Inc. reported revenues of --.
Earnings Growth
-
Bluejay Diagnostics, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Bluejay Diagnostics, Inc. reported earnings per share of -$1.01.
Enterprise value:
-1.5M
EV / Invested capital:
-0.38x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$159.4K
Return On Assets:
-108.46%
Net Income Margin (TTM):
--
Return On Equity:
-133.06%
Return On Invested Capital:
-127.98%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$793.6K | -$217.9K | -$159.4K | -$53.6K | -$31.6K | |
| Operating Income | -$10.4M | -$8.1M | -$7M | -$1.4M | -$1.6M | |
| EBITDA | -$9.6M | -$7.9M | -$6.8M | -$1.3M | -$1.6M | |
| Diluted EPS | -$3,875.31 | -$1,471.23 | -$32.24 | -$76.94 | -$1.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.8M | $13.9M | $6.5M | $6.6M | $3.3M | |
| Total Assets | $3.6M | $15.7M | $8.2M | $8.4M | $4.9M | |
| Current Liabilities | $4.7M | $1.5M | $2.8M | $1M | $1.1M | |
| Total Liabilities | $4.7M | $1.9M | $3M | $1.2M | $1.2M | |
| Total Equity | -$1.1M | $13.8M | $5.2M | $7.2M | $3.7M | |
| Total Debt | -- | $376.4K | $233.3K | $144.5K | $53.4K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.5M | -$8.9M | -$6.3M | -$2.2M | -$1.4M | |
| Cash From Investing | -$854.5K | -$393.6K | -$1.1K | -$200 | -- | |
| Cash From Financing | $1.1M | $10M | $3.7M | -$82.7K | -$1K | |
| Free Cash Flow | -$9.3M | -$9.3M | -$6.3M | -$2.2M | -$1.4M | |
BJDX
Sector
Market Cap
$1.5M
$27.9M
Price % of 52-Week High
7.84%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-133.43%
-1.49%
1-Year Price Total Return
-79.49%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.98
200-day SMA
Sell
Level
$1.96
Bollinger Bands (100)
Sell
Level
1.1 - 2.16
Chaikin Money Flow
Sell
Level
-138.3M
20-day SMA
Sell
Level
$1.15
Relative Strength Index (RSI14)
Sell
Level
22.53
ADX Line
Sell
Level
25.23
Williams %R
Buy
Level
-95.3107
50-day SMA
Sell
Level
$1.73
MACD (12, 26)
Sell
Level
-0.20
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
375.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.3629)
Sell
CA Score
(Annual)
Level (-4.9345)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (17.8155)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.
Stock Forecast FAQ
In the current month, BJDX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BJDX average analyst price target in the past 3 months is --.
-
Where Will Bluejay Diagnostics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bluejay Diagnostics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Bluejay Diagnostics, Inc.?
Analysts are divided on their view about Bluejay Diagnostics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bluejay Diagnostics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Bluejay Diagnostics, Inc.'s Price Target?
The price target for Bluejay Diagnostics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BJDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bluejay Diagnostics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BJDX?
You can purchase shares of Bluejay Diagnostics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bluejay Diagnostics, Inc. shares.
-
What Is The Bluejay Diagnostics, Inc. Share Price Today?
Bluejay Diagnostics, Inc. was last trading at $0.76 per share. This represents the most recent stock quote for Bluejay Diagnostics, Inc.. Yesterday, Bluejay Diagnostics, Inc. closed at $0.80 per share.
-
How To Buy Bluejay Diagnostics, Inc. Stock Online?
In order to purchase Bluejay Diagnostics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BJDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BJDX
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
0.39x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
BJDX
Sector
Revenue growth
--
4.62%
Earnings growth
98.68%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
BJDX
Sector
Profitability FY 2024
-$199.1K
$3.6M
Return on invested capital
-127.98%
-31.87%
Return on assets
-108.46%
-28.18%
Return on equity
-133.06%
-37.63%
Earnings Date
Last Earnings Date
Dec
22
Next Earnings Date
Dec
22
Estimated Next Earnings Date
Mar
23
Balance Sheet
BJDX
Sector
Total cash
$3.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$6.7M
$76.9M
Long term debt
$53.4K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
